Brazil Hemostats Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Flowable hemostatic gels are gaining prominence as an individual class in which the product has to mold itself according to the wound that is irregularly shaped instead of being dependent on a fixed sponge or patch form. The TRAUMAGEL by Cresilon is a plant-derived polysaccharide gel available in a 30 ml syringe and is ready to use directly on external bleeding points without any preparation process. The FDA 510(k) clearance for Cresilon was acquired in August 2024, and the product came into the market in January 2025. The technology creates a mechanical barrier at the wound and is intended for moderate-to-severe external bleeding. This format is particularly relevant to trauma and emergency applications where rapid, direct application is important.

Another trend related to product development is the removal of the need for refrigeration of certain absorbable haemostatic agents. In April 2025, Baxter launched a non-refrigerated version of the HEMOPATCH Sealing Hemostat in Europe. It is still a ready-to-use absorbable collagen pad designed for use in tissue sealing, dura sealing, and hemostasis, but the new storage format enables hospitals to store it right in the operating room without refrigerated storage. Baxter states that the change resulted from collaboration with surgeons and was intended to improve immediate availability during procedures. Such storage simplification can be particularly valuable for hospitals managing operating-room inventory across multiple surgical specialties.

The development of patches has gone beyond merely controlling blood loss into haemostatic patches that also seal tissues. ETHIZIA Hemostatic Sealing Patch by Ethicon utilizes activated polymer technology incorporated into a gelatin-based patch that can be controlled through stuffing, rolling, separating, cutting, and shaping it according to the needs of the surgical site. According to the clinical trial performed by Johnson & Johnson MedTech, ETHIZIA Hemostatic Sealing Patch attained haemostasis in 80% of patients in 30 seconds. This patch can be applied in both open and minimally invasive surgery and in organs for specific sites of bleeding. This creates a more versatile product category for surgeons dealing with difficult-to-control bleeding.

Haemostatic powders are evolving as procedure specific delivery devices, especially for gastrointestinal endoscopic procedures. Nexpowder Endoscopic Hemostasis System from Medtronic uses a powder that serves as an adhesive for difficult and active non-variceal bleeding in GI tract. Delivery device of this system is made in such a way that it avoids catheter occlusion and powder scatter without requiring any carbon dioxide or extra air compressor. The powder also changes into an adhesive gel when exposed to moisture, allowing it to interact with the bleeding site. This type of specialised endoscopic haemostat expands powder-based products beyond general surgical application and supports their use in gastroenterology, where conventional clipping or thermal methods may be difficult to apply.

The commercialization of plant-based polymers for haemostatic purposes instead of animal-based material is another factor resulting in market growth. According to Cresilon, TRAUMAGEL consists of plant-based polysaccharide materials and is not based on any animal product. When applied directly to the wound, the gel sticks to the wound and provides a physical barrier allowing the clot formation process. This approach is relevant to the haemostat landscape as material origin can become an important consideration for hospitals and clinicians when selecting products for different surgical and emergency applications.